[{"address1": "11400 West Olympic Boulevard", "address2": "Suite 200", "city": "Los Angeles", "state": "CA", "zip": "90064", "country": "United States", "phone": "310 651 8041", "website": "https://www.immixbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ilya  Rachman M.B.A., M.D., MBA, Ph.D.", "age": 50, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 669000, "exercisedValue": 0, "unexercisedValue": 1846232}, {"maxAge": 1, "name": "Mr. Gabriel  Morris B.A.", "age": 36, "title": "CFO & Director", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 669000, "exercisedValue": 0, "unexercisedValue": 3188312}, {"maxAge": 1, "name": "Dr. Graham  Ross FFPM, M.D.", "age": 63, "title": "Chief Medical Officer & Head of Clinical Development", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 104423, "exercisedValue": 0, "unexercisedValue": 55346}, {"maxAge": 1, "name": "Mr. Sean  Senn J.D., M.B.A., M.Sc., MBA, MSc", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.", "age": 76, "title": "Scientific Co-Founder", "yearBorn": 1947, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nandan  Oza B.S.", "age": 61, "title": "Head of Chemistry, Manufacturing & Control", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Marks", "title": "Chief Medical Officer of Cell Therapy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gerhard  Bauer", "title": "Head of Cell Therapy Manufacturing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.86, "open": 1.885, "dayLow": 1.8501, "dayHigh": 1.91, "regularMarketPreviousClose": 1.86, "regularMarketOpen": 1.885, "regularMarketDayLow": 1.8501, "regularMarketDayHigh": 1.91, "forwardPE": -3.080645, "volume": 55471, "regularMarketVolume": 55471, "averageVolume": 158104, "averageVolume10days": 239850, "averageDailyVolume10Day": 239850, "bid": 1.87, "ask": 1.93, "bidSize": 300, "askSize": 400, "marketCap": 52430456, "fiftyTwoWeekLow": 1.55, "fiftyTwoWeekHigh": 7.75, "fiftyDayAverage": 2.0888, "twoHundredDayAverage": 3.3331, "currency": "USD", "enterpriseValue": 29546478, "floatShares": 14027195, "sharesOutstanding": 27450500, "sharesShort": 578216, "sharesShortPriorMonth": 557402, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0219, "heldPercentInsiders": 0.40027002, "heldPercentInstitutions": 0.17820999, "shortRatio": 3.59, "shortPercentOfFloat": 0.0766, "impliedSharesOutstanding": 27450500, "bookValue": 0.871, "priceToBook": 2.1928818, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -19022096, "trailingEps": -0.83, "forwardEps": -0.62, "enterpriseToEbitda": -1.464, "52WeekChange": 0.17177916, "SandP52WeekChange": 0.24822903, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "IMMX", "underlyingSymbol": "IMMX", "shortName": "Immix Biopharma, Inc.", "longName": "Immix Biopharma, Inc.", "firstTradeDateEpochUtc": 1639665000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a16f90b7-2d1a-3bc1-ad13-b52d1a275ae3", "messageBoardId": "finmb_417356223", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.91, "targetHighPrice": 7.0, "targetLowPrice": 7.0, "targetMeanPrice": 7.0, "targetMedianPrice": 7.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 23975098, "totalCashPerShare": 0.873, "ebitda": -20180932, "totalDebt": 1091162, "quickRatio": 6.652, "currentRatio": 7.004, "debtToEquity": 4.567, "returnOnAssets": -0.56845003, "returnOnEquity": -1.03806, "freeCashflow": -9497338, "operatingCashflow": -14846913, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-15"}]